Summary
Objective
The aim of this study was to measure serum concentrations of human epididymis protein 4 (HE4) in premenopausal and postmenopausal women with benign adnexal tumors and compare HE4 levels with those of cancer antigen 125 (CA125) measured in the same samples.
Methods
In a retrospectively designed, monocentric study (Department of Gynecology & Obstetrics, General Hospital, Celje, Slovenia, EU), 147 women diagnosed with various benign adnexal tumors were included. Preoperative HE4 and CA125 levels were obtained and analyzed with regard to histopathological classification, menopausal status, and age distribution.
Results
A marked difference was observed in patients with endometriomas in which mean CA125 was elevated above the reference range in the premenopausal (mean 90.1 U/ml) and postmenopausal groups (mean 48.5 U/ml), while HE4 levels were within the reference range, irrespective of age or menopausal status. Inflammatory adnexal tumors were associated with elevated levels of CA125 (mean 142.2 U/ml, premenopausal and mean 62.4 U/ml, postmenopausal patients); HE4 levels were not elevated regardless of age or menopausal status.
Conclusion
HE4 is elevated less frequently than CA125 in benign adnexal tumors, regardless of age or menopausal status.
References
Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005;193(5):1630–9.
Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC Jr, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012;206(4):349.e1–349.e7. doi:10.1016/j.ajog.2011.12.028.
Park Y, Kim Y, Lee EY, Lee JH, Kim HS. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer. 2012;130(5):1136–44. doi:10.1002/ijc.26129.
Elecsys® CA 125 II. Available from: http://www.cobas.com/home/product/clinical-and-immunochemistry-testing/elecsys-ca-125.html via the INTERNET (accessed August 17 2016).
Elecsys® HE4 – Human epididymal protein 4. Available from: http://www.cobas.com/home/product/clinical-and-immunochemistry-testing/elecsys-human-epididymal-protein-4.html via the INTERNET (accessed August 17 2016).
Delić R, Weber V. Parasitic myoma as an adnexal mass: unexpected finding after vaginal hysterectomy. Acta Clin Croat. 2016;55(2):290–2. doi:10.20471/acc.2016.55.02.16
Bast RC Jr, Klug TL, John StE, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309(15):883.
Ueland FR, Li AJ. Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum. Available from: http://www.uptodate.com/contents/serum-biomarkers-for-evaluation-of-an-adnexal-mass-for-epithelial-carcinoma-of-the-ovary-fallopian-tube-or-peritoneum via the INTERNET (accessed January 11 2016).
Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011;104(5):863–70. doi:10.1038/sj.bjc.6606092.
Moore RG, Miller MC, Steinhoff MM, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012;206(4):351.e1–351.e8. doi:10.1016/j.ajog.2011.12.029.
Bolstad N, Oijordsbakken M, Nustad K, Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2012;33(1):141–8. doi:10.1007/s13277-011-0256-4.
Karlsen MA, Høgdall EV, Christensen IJ, et al. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer – An international multicenter study in women with an ovarian mass. Gynecol Oncol. 2015;138(3):640–6. doi:10.1016/j.ygyno.2015.06.021.
Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol. 2011;205(4):358.e1–358.e6. doi:10.1016/j.ajog.2011.05.017.
Patrelli TS, Berretta R, Gizzo S, et al. CA 125 serum values insurgically treated endometriosis patients and its relationships with anatomic sites of endometriosis and pregnancy rate. Fertil Steril. 2011;95(1):393–6. doi:10.1016/j.fertnstert.2010.08.043.
Cheng YM, Wang ST, Chou CY. Serum CA-125 in preoperative patients at high risk for endometriosis. Obstet Gynecol. 2002;99(3):375–80.
Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumors from ovarian endometriotic cysts. Br J Cancer. 2009;100(8):1315–9. doi:10.1038/sj.bjc.6605011.
Pagana KD, Pagana TJ, Pagana TN. CA-125 tumor marker (Cancer antigen-125). In: Mosby’s diagnostic and laboratory test reference, 12th edn. St. Louis: Elselvier Mosby; 2015. pp. 199–200.
Moley KH, Massad LS, Mutch DG. Pelvic inflammatory disease. Correlation of severity with CA-125 levels. J Reprod Med. 1996;41(5):341–6.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
R. Delić, M. Štefanović, Š. Krivec, V. Weber, and J. Koren declare that they have no competing interests.
Ethical standards
The study was approved by the Slovenian National Medical Ethics Committee.
Rights and permissions
About this article
Cite this article
Delić, R., Štefanović, M., Krivec, Š. et al. Comparison of HE4 and CA125 levels in women with benign gynecologic disorders. Wien Klin Wochenschr 128 (Suppl 7), 543–547 (2016). https://doi.org/10.1007/s00508-016-1099-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00508-016-1099-1